Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2019

View Archived Issues

Skin microbiome study gives insights into wound healing

Why PD-1 isn't CTLA-4

Targeting FATP2 tames myeloid suppressor cells

Enanta Pharmaceuticals MAP3K5 inhibitor active in models of liver injury, metabolic disease

Zhejiang Hisun Pharmaceutical divulges new SCN9A blockers

Zonula presents CDH2 antagonists

BioAtla's conditionally active biologics show tumor-specific activity in vivo

Phase IIb data presented for CT-P27 in adults with influenza A infection

TXA-9155 potentiates antibiotics against Pseudomonas aeruginosa

Topline results from phase III study of tanezumab in osteoarthritis

FDA approves Keytruda for use with Inlyta in first-line advanced renal cell carcinoma

Forbius doses first patient with triple-negative breast cancer in phase IIa trial of AVID-100

FDA accepts IND for HER2-targeting engineered toxin body MT-5111

Fochon Pharma advances new anticancer Bcl-2, CDK4/6 inhibitors

Vaxiion to begin phase I study of VAX-014 in bladder cancer

Terns Pharmaceuticals presents preclinical data for TERN-201 in NASH models

New phase III trial in China explores combination of furaprevir and yimitasvir for chronic HCV

Phase III COAST-X study of Taltz in nonradiographic axial spondyloarthritis meets key endpoints

Vicore to develop VP-01 for diffuse systemic sclerosis

Phase I results for OP-0201 in healthy adults and adults with acute otitis media

Indalo initiates phase I study of antifibrotic drug candidate IDL-2965

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...